The Saudi Journal of Gastroenterology (Jan 2016)

The prognostic value of UHRF-1 and p53 in gastric cancer

  • Nalan A Babacan,
  • Hatice Reyhan Egilmez,
  • Birsen Yücel,
  • Parlak Ilknur,
  • Mehmet Metin Seker,
  • Turgut Kaçan,
  • Aykut Bahçeci,
  • Sener Cihan,
  • Bülent Akinci,
  • Berna Eriten,
  • Saadettin Kiliçkap

DOI
https://doi.org/10.4103/1319-3767.173755
Journal volume & issue
Vol. 22, no. 1
pp. 25 – 29

Abstract

Read online

Background/Aims: This study aimed to examine whether UHRF-1 and p53 overexpression is a prognostic marker for gastric cancer. Patients and Methods: Sixty-four patients with gastric cancer (study group) and 23 patients with gastritis (control group) were evaluated. Immunohistochemistry was used to examine expression of UHRF-1 and p53 in gastric cancers and a control group diagnosed with gastritis. Results: The median age was 63 years (18-83 years) in the study group. UHRF-1 was positive in 15 (23%) patients with gastric cancer and fi ve (21.7%) patients with gastritis (P = 0.559). UHRF1 expression level in gastric cancer is more powerful than in gastritis (P = 0.046). Thirty-seven (61%) patients with gastric cancer and only one patient with gastritis were p53 positive (P < 0.001). After a median follow-up of 12 months (1-110), the 2-year overall survival rates were 55% and 30% in negative and positive p53, respectively (P = 0.084). Also, the 2-year overall survival rates were 45% and 53% in negative and positive UHRF-1, respectively (P = 0.132). Conclusion: According to this study, UHRF-1and p53 were not prognostic factors for gastric cancer, whereas they may have a diagnostic value for differantiating between gastric cancer and gastritis.

Keywords